Personalizing therapy of urogenital cancer by metastatic tissue Immune profiling, Organoid culture, and NExt genERation sequencing

Recruiting

• Conditions: Urigenital cancer; bladder cancer and prostate cancer; 10038364

• Registration Number: NL-OMON46194
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 150

Inclusion Criteria

- Patients with metastasized bladder cancer or prostate cancer

Exclusion Criteria

- Comorbidity that interferes with the safe removal of extra tissue.
- Objection against anonymized storage of tissue for an unlimited period of time.
- Objection against disclosure of relevant incidental findings (DNA sequencing).

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Percentage of organoid cultures with >2 passages and percentage of<br /><br>organoid-lines (>4 passages).<br /><br>- Percentage of organoids in which the DNA profile shows strong concordance<br /><br>with the DNA profile of biopsy tissue (>70% concordance regarding aberrations<br /><br>of snvs/InDels/CNVs)<br /><br>- Therapies for which a factor 3 difference in cell viability is found between<br /><br>organoids with and organoids without aberrations in the targeted pathway.<br /><br></p><br>